Top

Published in:

01-02-2012 | Laboratory Investigation - Human/Animal Tissue

HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis

Authors: Bo Pang, Haitao Fan, Ian Y. Zhang, Bin Liu, Bin Feng, Lei Meng, Rui Zhang, Sam Sadeghi, Hua Guo, Qi Pang

Published in: Journal of Neuro-Oncology | Issue 3/2012

Abstract

High-mobility group A1 (HMGA1) protein is an architectural transcription factor widely expressed during embryonic development and tumor progression. The purpose of this research was to investigate the expression of HMGA1 in malignant gliomas with different WHO classification and to study the correlation of HMGA1 expression with tumor proliferation, invasion, and angiogenesis. Expression of HMGA1, Ki-67, MMP-9, VEGF-A, and MVD in malignant gliomas and their correlation were studied in 60 samples of different WHO classification by use of immunohistochemistry, and in 27 randomly selected samples by use of real-time quantitative PCR. Immunohistochemistry results showed that nuclear immunostaining of HMGA1 protein was not observed in normal brain tissues but was observed in 96.7% (58 of 60) of malignant gliomas including high (+++) in 15 (25.0%), moderate (++) in 28 (46.7%), and negligible to low (0–+) in 17 (28.3%) samples. Expression of HMGA1 protein was significantly higher in glioblastoma multiforme than in WHO grade II (P = 0.002) and WHO grade III gliomas (P = 0.024). HMGA1 protein expression correlated significantly with expression of Ki-67 (r = 0.530, P = 0.000), MMP-9 (r = 0.508, P = 0.000), VEGF-A (r = 0.316, P = 0.014), and MVD (r = 0.321, P = 0.012), but not with sex (r = 0.087, P = 0.510) and age (r = −0.121, P = 0.358). Real-time quantitative PCR results, also, were indicative of HMGA1 overexpression in glioblastoma multiforme compared with WHO grade II (P = 0.043) and WHO grade III (P = 0.031) gliomas. HMGA1 gene expression correlated significantly with gene expression of Ki-67 (r = 0.429, P = 0.025), MMP-9 (r = 0.443, P = 0.024), and VEGF-A (r = 0.409, P = 0.034). These results indicated that expression of HMGA1 correlates significantly with malignancy, proliferation, invasion, and angiogenesis of gliomas. We conclude that HMGA1 may be a potential biomarker and rational therapeutic target for human tumors.

Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML (1999) The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 85:485–491PubMedCrossRef

Ranuncolo SM, Varela M, Morandi A, Lastiri J, Christiansen S, Bal de Kier Joffe E, Pallotta MG, Puricelli L (2004) Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J Neurooncol 68:113–121PubMedCrossRef

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507PubMedCrossRef

Matsuda M, Nimura K, Shimbo T, Hamasaki T, Yamamoto T, Matsumura A, Kaneda Y (2010) Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. J Neurooncol. dio:10.1007/s11060-010-0355-x

Germano IM, Binello E (2009) Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. J Neurooncol 93:79–87PubMedCrossRef

Chiocca EA, Broaddus WC, Gillies GT, Visted T, Lamfers ML (2004) Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neurooncol 69:101–117PubMedCrossRef

Jacobs AH, Voges J, Kracht LW, Dittmar C, Winkeler A, Thomas A, Wienhard K, Herholz K, Heiss WD (2003) Imaging in gene therapy of patients with glioma. J Neurooncol 65:291–305PubMedCrossRef

Grasser KD (2003) Chromatin-associated HMGA and HMGB proteins: versatile co-regulators of DNA-dependent processes. Plant Mol Biol 53:281–295PubMedCrossRef

Fan H, Guo H, Zhang IY, Liu B, Luan L, Xu S, Hou X, Liu W, Zhang R, Wang X, Pang Q (2011) The different HMGA1 expression of total population of glioblastoma cell line U251 and glioma stem cells isolated from U251. Brain Res 1384:9–14PubMedCrossRef

10.

Johnson KR, Lehn DA, Reeves R (1989) Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 9:2114–2123PubMed

11.

Reeves R, Nissen MS (1990) The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265:8573–8582PubMed

12.

Lovell-Badge R (1995) Developmental genetics. Living with bad architecture. Nature 376:725–726PubMedCrossRef

13.

Reeves R, Beckerbauer L (2001) HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519:13–29PubMed

14.

Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A, Manfioletti G, Giancotti V (2004) Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 574:1–8PubMedCrossRef

15.

Fedele M, Fusco A (2010) HMGA and cancer. Biochim Biophys Acta 1799:48–54PubMed

16.

Fusco A, Fedele M (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7:899–910PubMedCrossRef

17.

Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A, Fusco A (1996) High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13:2439–2446PubMed

18.

Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H (1998) The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 23:350–357PubMedCrossRef

19.

Zhou X, Benson KF, Ashar HR, Chada K (1995) Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376:771–774PubMedCrossRef

20.

Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V, Fusco A (1995) The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 10:1307–1314PubMed

21.

Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Manfioletti G, Casamassimi A, Santoro M, Giancotti V, Fusco A (1996) Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 56:1896–1901PubMed

22.

Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V, Fusco A (1998) Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 58:4193–4198PubMed

23.

Kim DH, Park YS, Park CJ, Son KC, Nam ES, Shin HS, Ryu JW, Kim DS, Park CK, Park YE (1999) Expression of the HMGI(Y) gene in human colorectal cancer. Int J Cancer 84:376–380PubMedCrossRef

24.

Chiappetta G, Botti G, Monaco M, Pasquinelli R, Pentimalli F, Di Bonito M, D’Aiuto G, Fedele M, Iuliano R, Palmieri EA, Pierantoni GM, Giancotti V, Fusco A (2004) HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res 10:7637–7644PubMedCrossRef

25.

Frasca F, Rustighi A, Malaguarnera R, Altamura S, Vigneri P, Del Sal G, Giancotti V, Pezzino V, Vigneri R, Manfioletti G (2006) HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res 66:2980–2989PubMedCrossRef

26.

Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M, Hillion JA, Belton A, Joseph B, Schuldenfrei A, Iacobuzio-Donahue CA, Maitra A, Resar LM (2010) HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 23:98–104PubMedCrossRef

27.

Mu G, Liu H, Zhou F, Xu X, Jiang H, Wang Y, Qu Y (2010) Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. Hum Pathol 41:493–502PubMedCrossRef

28.

Enestrom S, Vavruch L, Franlund B, Nordenskjold B (1998) Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochirurgie 44:25–30PubMed

29.

Johannessen AL, Torp SH (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 12:143–147PubMedCrossRef

30.

Wild-Bode C, Weller M, Wick W (2001) Molecular determinants of glioma cell migration and invasion. J Neurosurg 94:978–984PubMedCrossRef

31.

Raithatha SA, Muzik H, Rewcastle NB, Johnston RN, Edwards DR, Forsyth PA (2000) Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol 2:145–150PubMed

32.

Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS (2002) Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 8:2894–2901PubMed

33.

Goldbrunner RH, Bernstein JJ, Plate KH, Vince GH, Roosen K, Tonn JC (1999) Vascularization of human glioma spheroids implanted into rat cortex is conferred by two distinct mechanisms. J Neurosci Res 55:486–495PubMedCrossRef

34.

Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848PubMedCrossRef

35.

Rotondo F, Sharma S, Scheithauer BW, Horvath E, Syro LV, Cusimano M, Nassiri F, Yousef GM, Kovacs K (2010) Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes. Neoplasma 57:590–593PubMedCrossRef

36.

Kosem M, Tuncer I, Kotan C, Ibiloglu I, Ozturk M, Turkdogan MK (2009) Significance of VEGF and microvascular density in gastric carcinoma. Hepatogastroenterology 56:1236–1240PubMed

37.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C (T)) method. Methods 25:402–408PubMedCrossRef

38.

Reeves R, Edberg DD, Li Y (2001) Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 21:575–594PubMedCrossRef

39.

Zhang Y, Ma T, Yang S, Xia M, Xu J, An H, Yang Y, Li S (2011) High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. Mol Cell Biochem. doi: 10.1007/s11010-011-0907-1

40.

Palmieri D, Valentino T, D’Angelo D, De Martino I, Postiglione I, Pacelli R, Croce CM, Fedele M, Fusco A (2011) HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene doi: 10.1038/onc.2011.21

41.

Cao YD, Huang PL, Sun XC, Ma J, Jin ZL, Cheng HY, Xu RZ, Li F, Qin SK, Deng YX, Ge XL (2011) Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells. Chin Med J (Engl) 124:1061–1068

42.

Yuan S, Pan Q, Fu C, Bi Z (2011) Silencing of HMGA1 expression by RNA interference suppresses growth of osteogenic sarcoma. Mol Cell Biochem doi: 10.1007/s11010-011-0865-7

43.

Scheithauer BW, Fuller GN, VandenBerg SR (2008) The 2007 WHO classification of tumors of the nervous system: controversies in surgical neuropathology. Brain Pathol 18:307–316PubMedCrossRef

Title: HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis
Authors: Bo Pang
Haitao Fan
Ian Y. Zhang
Bin Liu
Bin Feng
Lei Meng
Rui Zhang
Sam Sadeghi
Hua Guo
Qi Pang
Publication date: 01-02-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0710-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience

Incidental brain lesions in children: to treat or not to treat?

Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life

Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells

Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results

Erratum to: Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life